Literature DB >> 22155653

Increased cholecystokinin labeling in the hippocampus of a mouse model of epilepsy maps to spines and glutamatergic terminals.

M S Wyeth1, N Zhang, C R Houser.   

Abstract

The neuropeptide cholecystokinin (CCK) is abundant in the CNS and is expressed in a subset of inhibitory interneurons, particularly in their axon terminals. The expression profile of CCK undergoes numerous changes in several models of temporal lobe epilepsy. Previous studies in the pilocarpine model of epilepsy have shown that CCK immunohistochemical labeling is substantially reduced in several regions of the hippocampal formation, consistent with decreased CCK expression as well as selective neuronal degeneration. However, in a mouse pilocarpine model of recurrent seizures, increases in CCK-labeling also occur and are especially striking in the hippocampal dendritic layers of strata oriens and radiatum. Characterizing these changes and determining the cellular basis of the increased labeling were the major goals of the current study. One possibility was that the enhanced CCK labeling could be associated with an increase in GABAergic terminals within these regions. However, in contrast to the marked increase in CCK-labeled structures, labeling of GABAergic axon terminals was decreased in the dendritic layers. Likewise, cannabinoid receptor 1-labeled axon terminals, many of which are CCK-containing GABAergic terminals, were also decreased. These findings suggested that the enhanced CCK labeling was not due to an increase in GABAergic axon terminals. The subcellular localization of CCK immunoreactivity was then examined using electron microscopy, and the identities of the structures that formed synaptic contacts were determined. In pilocarpine-treated mice, CCK was observed in dendritic spines and these were proportionally increased relative to controls, whereas the proportion of CCK-labeled terminals forming symmetric synapses was decreased. In addition, CCK-positive axon terminals forming asymmetric synapses were readily observed in these mice. Double labeling with vesicular glutamate transporter 1 and CCK revealed colocalization in numerous terminals forming asymmetric synapses, confirming the glutamatergic identity of these terminals. These data raise the possibility that expression of CCK is increased in hippocampal pyramidal cells in mice with recurrent, spontaneous seizures.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155653      PMCID: PMC3268850          DOI: 10.1016/j.neuroscience.2011.11.056

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  90 in total

1.  Excitatory effects of cholecystokinin in rat hippocampus: pharmacological response compatible with 'central'- or B-type CCK receptors.

Authors:  G A Böhme; J M Stutzmann; J C Blanchard
Journal:  Brain Res       Date:  1988-06-07       Impact factor: 3.252

2.  Dendritic but not somatic GABAergic inhibition is decreased in experimental epilepsy.

Authors:  R Cossart; C Dinocourt; J C Hirsch; A Merchan-Perez; J De Felipe; Y Ben-Ari; M Esclapez; C Bernard
Journal:  Nat Neurosci       Date:  2001-01       Impact factor: 24.884

3.  Gastrin is a major mediator of the gastric phase of acid secretion in dogs: proof by monoclonal antibody neutralization.

Authors:  T O Kovacs; J H Walsh; V Maxwell; H C Wong; T Azuma; E Katt
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

4.  Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons.

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

5.  Autoradiographic Localization of Cholecystokinin A and B Receptors in Rat Brain Using [125I]d-Tyr25 (Nle28,31)-CCK 25 - 33S.

Authors:  M. Carlberg; A. L. Gundlach; L. D. Mercer; P. M. Beart
Journal:  Eur J Neurosci       Date:  1992       Impact factor: 3.386

6.  Somatostatin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy.

Authors:  C Schwarzer; J M Williamson; E W Lothman; A Vezzani; G Sperk
Journal:  Neuroscience       Date:  1995-12       Impact factor: 3.590

7.  Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers.

Authors:  C Gall
Journal:  J Neurosci       Date:  1988-06       Impact factor: 6.167

8.  Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others.

Authors:  Miranda A Karson; Kevin C Whittington; Bradley E Alger
Journal:  Neuropharmacology       Date:  2007-07-01       Impact factor: 5.250

9.  Brain cholecystokinin and nutritional status in rats and mice.

Authors:  B S Schneider; J W Monahan; J Hirsch
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

10.  Anticonvulsant effects of caerulein, cholecystokinin octapeptide (CCK-8) and diazepam against seizures produced in mice by harman, thiosemicarbazide and isoniazid.

Authors:  G Zetler
Journal:  Neurosci Lett       Date:  1981-07-02       Impact factor: 3.046

View more
  10 in total

1.  Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain.

Authors:  Katherine W Sayers; Peter T Nguyen; Robert E Blair; Laura J Sim-Selley; Robert J DeLorenzo
Journal:  Epilepsia       Date:  2012-04-17       Impact factor: 5.864

Review 2.  Neuropeptide transmission in brain circuits.

Authors:  Anthony N van den Pol
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

3.  The neurotoxic effects of ampicillin-associated gut bacterial imbalances compared to those of orally administered propionic acid in the etiology of persistent autistic features in rat pups: effects of various dietary regimens.

Authors:  Afaf El-Ansary; Ramesa Shafi Bhat; Sooad Al-Daihan; Abeer M Al Dbass
Journal:  Gut Pathog       Date:  2015-03-22       Impact factor: 4.181

4.  Potential Pleiotropic Genes and Shared Biological Pathways in Epilepsy and Depression Based on GWAS Summary Statistics.

Authors:  Han Lin; Wan-Hui Lin; Feng Lin; Chang-Yun Liu; Chun-Hui Che; Hua-Pin Huang
Journal:  Comput Intell Neurosci       Date:  2022-04-12

5.  Ectopic Expression of α6 and δ GABAA Receptor Subunits in Hilar Somatostatin Neurons Increases Tonic Inhibition and Alters Network Activity in the Dentate Gyrus.

Authors:  Xiaoping Tong; Zechun Peng; Nianhui Zhang; Yliana Cetina; Christine S Huang; Martin Wallner; Thomas S Otis; Carolyn R Houser
Journal:  J Neurosci       Date:  2015-12-09       Impact factor: 6.167

6.  What Happened in the Hippocampal Axon in a Rat Model of Posttraumatic Stress Disorder.

Authors:  Yadi Guan; Xinzhao Chen; Beiying Zhao; Yuxiu Shi; Fang Han
Journal:  Cell Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.046

7.  Hippocampal gene expression meta-analysis identifies aging and age-associated spatial learning impairment (ASLI) genes and pathways.

Authors:  Raihan K Uddin; Shiva M Singh
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

Review 8.  Neuropeptides as targets for the development of anticonvulsant drugs.

Authors:  Elke Clynen; Ann Swijsen; Marjolein Raijmakers; Govert Hoogland; Jean-Michel Rigo
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

9.  Loss of Either Rac1 or Rac3 GTPase Differentially Affects the Behavior of Mutant Mice and the Development of Functional GABAergic Networks.

Authors:  Roberta Pennucci; Francesca Talpo; Veronica Astro; Valentina Montinaro; Lorenzo Morè; Marco Cursi; Valerio Castoldi; Sara Chiaretti; Veronica Bianchi; Silvia Marenna; Marco Cambiaghi; Diletta Tonoli; Letizia Leocani; Gerardo Biella; Patrizia D'Adamo; Ivan de Curtis
Journal:  Cereb Cortex       Date:  2015-11-17       Impact factor: 5.357

Review 10.  Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.

Authors:  Santiago J Ballaz; Michel Bourin
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.